Aarti Drugs Ltd. News and Updates

Name: Latest research reports of Aarti Drugs Ltd. authored by Axis Direct and published by - Trendlyne research reports.
Item: Aarti Drugs Ltd.
Rating: 5
Author: Axis Direct

Keep track of all breaking news on Aarti Drugs Ltd. from all sources in a single place.

Load latest

Aarti Drugs Ltd.

28 Jan 2024

361.50

1.13%

Aarti Drugs Q3 Results Review - Negative Rate Variance Impacts API Sales: Dolat Capital

NDTV Profit

Demand slowdown in exports & lower realization impacts API growth.

Aarti Drugs Ltd. has an average target of 470.00 from 1 broker.

Aarti Drugs Ltd.

25 Jan 2024

361.50

1.13%

Aarti Drugs Results Earnings Call for Q3FY24

Conference Call with Aarti Drugs Management and Analysts on Q3FY24 Performance and Outlook. Listen to the full earnings transcript.

audio

Aarti Drugs Ltd.

28 Nov 2023

361.50

1.13%

Aarti Drugs listed as top pick of the week' by Axis Securities 4 key reasons

livemint

The brokerage has a buy' recommendation on the stock with a target price of 528, indicating an upside of 10 percent from its current market price of 480.30.

Aarti Drugs Ltd. is trading above its 30 day SMA of 347.1

Aarti Drugs Ltd.

20 Oct 2023, 01:26PM

361.50

1.13%

Aarti Drugs Results Earnings Call for Q2FY24

Conference Call with Aarti Drugs Management and Analysts on Q2FY24 Performance and Outlook. Listen to the full earnings transcript.

audio

Aarti Drugs Ltd.

20 Oct 2023, 10:21AM

361.50

1.13%

to see Rapid results content

Aarti Drugs Ltd.

20 Oct 2023, 12:00AM

361.50

1.13%

Result Update:Aarti Drugs

Buy: Aarti Drugs Ltd.

Target

Axis Direct

We expect demand for API to continue in the upcoming quarters with easing supply chain bottlenecks. We believe that Aarti Drugs, being a leader in the domestic industry, is well-placed to capitalize on prevalent as well as future growth opportunities.

Aarti Drugs Ltd. has an average target of 470.00 from 1 broker.

Aarti Drugs Ltd.

13 Sep 2023

361.50

1.13%

Aarti Drugs jumps 4%, partly recoups last two days' losses

Moneycontrol

As many as 3.3 lakh shares of Aarti Drugs were traded on the exchanges till afternoon

Aarti Drugs Ltd. has lost -27.68% in the last 6 Months

Aarti Drugs Ltd.

25 Jul 2023

361.50

1.13%

Result Update:Aarti Drugs

Buy: Aarti Drugs Ltd.

Target

Axis Direct

We believe that Aarti Drugs, being a leader in the domestic industry, is well-placed to capitalize on prevalent as well as future growth opportunities. We have BUY rating on stock.

Aarti Drugs Ltd. is trading above its 30 day SMA of 347.1

Aarti Drugs Ltd.

24 Jul 2023

361.50

1.13%

to see Rapid results content

Aarti Drugs Ltd.

24 Jul 2023

361.50

1.13%

Aarti Drugs shares surge over 16% on buyback approval

Business Line

Aarti Drugs's stock witnessed a significant rise of 16.30% after the company's board approved a buyback of shares at 900 per share, representing 0.72% of the existing paid-up capital.